Zobrazeno 1 - 8 of 8 pro vyhledávání: '"Megan Kearney"'
2
Feasibility of digital pathology of circulating tumor cells with morphologic analysis in localized bladder cancer
Autor: Michael H. Johnson, Andres Matoso, Megan Fong, Jean H. Hoffman-Censits, Andrea B. Apolo, David J. McConkey, Kelly T. Harris, Michael A. Gorin, Max Kates, Stephanie Glavaris, Heather J. Chalfin, Kenneth J. Pienta, Megan Kearney, Noah M. Hahn, Trinity J. Bivalacqua, Vladimir Valera, Adam Jendrisak
Publikováno v: Journal of Clinical Oncology. 38:525-525
525 Background: Circulating tumor cells (CTCs) are promising biomarkers in metastatic urothelial cancer (UC). Unfortunately, efforts in localized disease have been unsuccessful, in part due to limitations of existing technologies that rely on countin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cf28f60539ed5bd6dc8a7a367119e862
https://doi.org/10.1200/jco.2020.38.6_suppl.525
Zobrazit plný text záznamu
3
Abstract P4-01-09: Phenotypic profiling of circulating tumor cells (CTCs) in patients with metastatic breast cancer reveals clinically-relevant heterogeneity in CTC morphology and marker expression
Autor: Nadia Ebrahim, Joseph D. Schonhoft, Adam Jendrisak, Lincy Chu, Priscilla Ontiveros, Megan Kearney, Rick Wenstrup, Yipeng Wang, Tiziano Pramparo
Publikováno v: Cancer Research. 80:P4-01
Background: The choice between hormonal therapies and chemotherapy is a frequent decision in the standard of care of metastatic breast cancer (mBCa) patients. We previously developed quantitative measures of phenotypic CTC heterogeneity in metastatic
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5ee7040e62f7754a42887438fc682f06
https://doi.org/10.1158/1538-7445.sabcs19-p4-01-09
Zobrazit plný text záznamu
4
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer
Autor: Andrea Sboner, Samaneh Motanagh, Megan Kearney, David S. Rickman, David M. Nanus, Yuzhuo Wang, Himisha Beltran, Loredana Puca, Kumiko Isse, Judy Hess, Adam J. Donoghue, Michael Sigouros, Juan Miguel Mosquera, Verena Sailer, Scott T. Tagawa, Etienne Dardenne, Katie Gavyert, Laura Saunders, Olivier Elemento, Ryan Dittamore, Heng Pan, Luisa Fernandez, Aram Vosoughi, Vincenza Conteduca
Publikováno v: Università degli studi di Foggia-IRIS
Histologic transformation to small cell neuroendocrine prostate cancer occurs in a subset of patients with advanced prostate cancer as a mechanism of treatment resistance. Rovalpituzumab tesirine (SC16LD6.5) is an antibody-drug conjugate that targets
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fc8c414d55fd5d1b095ffe2dba7a20f
https://pubmed.ncbi.nlm.nih.gov/31040438
Zobrazit plný text záznamu
5
SLFN11 expression (exp) in castration-resistant prostate cancer (CRPC) patients (pts) to predict response to platinum-based chemotherapy (PLT)
Autor: David M. Nanus, Judy Hess, Scott T. Tagawa, Himisha Beltran, Michael Sigouros, Ryan Dittamore, Loredana Puca, Sheng-Yu Ku, Panagiotis J. Vlachostergios, Juan Miguel Mosquera, Rohan Bareja, Olivier Elemento, Vincenza Conteduca, Luisa Fernandez, Megan Kearney, Andrea Sboner
Publikováno v: Journal of Clinical Oncology. 37:5065-5065
5065 Background: Schlafen family member 11 (SLFN11) sensitizes tumor cells to DNA-damaging agents and has been investigated as a potential predictive biomarker of response to PLT and PARP inhibitors, especially in small cell lung cancer (Lok, CCR 201
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cb6fb7f0e18557749e9d0f22083084bb
https://doi.org/10.1200/jco.2019.37.15_suppl.5065
Zobrazit plný text záznamu
7
PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs
Autor: Daniel P. Petrylak, Michael J. Morris, A. Oliver Sartor, Nicholas J. Vogelzang, Mark Landers, Michael S. Gordon, Adam Robarts, Anthony W. Tolcher, Michael Groaning, Phillip H. Kuo, Yipeng Wang, Adam Jendrisak, Richard A. Messmann, Megan Kearney, Hani M. Babiker, Alison Armour
Publikováno v: Journal of Clinical Oncology. 36:272-272
272 Background: Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancers, making it an ideal imaging and therapeutic target of interest. The utility of the PSMA-targeted imaging agent 99mTc-EC0652 is being evaluated, along wi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0807e00d773481b525545e3a19fc7d20
https://doi.org/10.1200/jco.2018.36.6_suppl.272
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje